Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar;41(3):303-311.
doi: 10.1007/s40264-017-0616-0.

Using Human 'Experiments of Nature' to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors

Rebecca N Jerome  1 , Jill M Pulley  2 , Dan M Roden  3 , Jana K Shirey-Rice  2 , Lisa A Bastarache  4 , Gordon R Bernard  2   3 , Leeland B Ekstrom  2   5 , William J Lancaster  4 , Joshua C Denny  4
Affiliations

Using Human 'Experiments of Nature' to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors

Rebecca N Jerome et al. Drug Saf. 2018 Mar.

Abstract

Introduction: When a new drug enters the market, its full array of side effects remains to be defined. Current surveillance approaches targeting these effects remain largely reactive. There is a need for development of methods to predict specific safety events that should be sought for a given new drug during development and postmarketing activities.

Objective: We present here a safety signal identification approach applied to a new set of drug entities, inhibitors of the serine protease proprotein convertase subtilisin/kexin type 9 (PCSK9).

Methods: Using phenome-wide association study (PheWAS) methods, we analyzed available genotype and clinical data from 29,722 patients, leveraging the known effects of changes in PCSK9 to identify novel phenotypes in which this protein and its inhibitors may have impact.

Results: PheWAS revealed a significantly reduced risk of hypercholesterolemia (odds ratio [OR] 0.68, p = 7.6 × 10-4) in association with a known loss-of-function variant in PCSK9, R46L. Similarly, laboratory data indicated significantly reduced beta mean low-density lipoprotein cholesterol (- 14.47 mg/dL, p = 2.58 × 10-23) in individuals carrying the R46L variant. The R46L variant was also associated with an increased risk of spina bifida (OR 5.90, p = 2.7 × 10-4), suggesting that further investigation of potential connections between inhibition of PCSK9 and neural tube defects may be warranted.

Conclusion: This novel methodology provides an opportunity to put in place new mechanisms to assess the safety and long-term tolerability of PCSK9 inhibitors specifically, and other new agents in general, as they move into human testing and expanded clinical use.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Signal detection overview: Validation and novel phenotypes Note: Green arrows correspond with beneficial effects of reduced PCSK9; red arrows correspond with potentially harmful effects of reduced PCSK9.
Figure 2
Figure 2
Potential paths by which PCSK9 may contribute to development of spina bifida
See this image and copyright information in PMC

Comment in

References

    1. Cruz ML, Xu J, Kashoki M, Lurie P. Publication and Reporting of the Results of Postmarket Studies for Drugs Required by the US Food and Drug Administration, 2009 to 2013. JAMA Intern Med [Internet] 2017 [cited 2017 May 17]; Available from: http://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2626857. - PMC - PubMed
    1. Noel ZR, Beavers CJ. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Brief Overview. Am J Med. 2017;130:229.e1–229.e4. - PubMed
    1. Abifadel M, Varret M, Rabès J-P, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154–6. - PubMed
    1. Stein EA, Raal F. Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. Annu Rev Med. 2014;65:417–31. - PubMed
    1. Schmidt AF, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2017;4:CD011748. - PMC - PubMed

Publication types